Doctors Frustrated By Lack Of Guidance On Who Should Get Aduhelm
Broad Label Has No Requirement To Test For Amyloid
Executive Summary
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.
You may also be interested in...
Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It
The Biogen/Eisai drug may have a disease-modifying impact on Alzheimer’s progression but the lack of published evidence is still causing prescriber reluctance and hampering reimbursement decisions.
Looking Past Aduhelm, Biogen Puts Pipeline On Display
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
Aduhelm’s Revised Labeling Could Help Payers Navigate Reimbursement
The US FDA revised labeling to clarify the target population, which could be helpful in reimbursement discussions for the Alzheimer's therapy.